Loop diuretics are recommended for relieving symptoms and signs of congestion in patients with chronic heart failure and are administered to more than 80% of them. However, several of their effects have not systematically been studied. Numerous cohort and four interventional studies have addressed the effect of diuretics on renal function; apart from one prospective study, which showed that diuretics withdrawal is accompanied by increase in some markers of early-detected renal injury, all others converge to the conclusion that diuretics receipt, especially in high doses is associated with increased rates of renal dysfunction. Although a long standing perception has attributed a beneficial effect to diuretics in the setting of chronic heart failure, many cohort studies support that their use, especially in high doses is associated with adverse outcome. Several studies have used propensity scores in order to match diuretic and non-diuretic receiving patients; their results reinforce the notion that diuretics use and high diuretics dose are true risk factors and not disease severity markers, as some have suggested. One small, randomized study has demonstrated that diuretics decrease is feasible and safe and accompanied by a better prognosis. In conclusion, until elegantly designed, randomized trials, powered for clinical endpoints answer the unsettled issues in the field, the use of diuretics in chronic heart failure will remain subject to physicians' preferences and biases and not evidence based.
Introduction
Despite the breakthroughs witnessed over the past decades with regards to the outpatient management of patients with heart failure (HF), diuretics remain the mainstay of treatment for relieving congestion-related symptoms and signs in these patients. Diuretics are accompanied by a class I recommendation for this indication. 1, 2 However, this recommendation is supported only by expert opinions and one meta-analysis, 3 the quality of which has been questioned 4 ; the paucity of supporting data derived from large-scale, randomized studies with 'hard' clinical endpoints is unequivocal.
The rationale of this review is to approach current evidence for loop diuretic therapy in chronic HF (CHF) from a viewpoint which is focused on diuretic effects on more 'hard' endpoints: renal dysfunction, hospitalizations, and survival. For this purpose the PubMed database was employed. On this website, we searched for articles between 1985 and July 2016 using the key terms 'chronic heart failure' AND 'diuretics'. We decided to use as a rule of thumb the fact that the abstracts of those articles that indicated in the title that they might have evaluated the effect of diuretics effect on renal function, hospitalizations or survival were to be read. The entire article was read if the abstract indicated that the article potentially met the inclusion criteria. Articles were included in the review according to the following inclusion criteria: English language, year of publication from 1985 and report of diuretics effect on the aforementioned endpoints. Articles were excluded by title, abstract or full text for irrelevance to the topic in question. Further exclusion criteria were article reviews and editorial comments. Two independent reviewers CJK and KM performed the literature search and data extraction. In case of a disagreement between the two reviewers the input of a third more senior reviewer (EK) was requested.
Effects of loop diuretics on renal function
Renal dysfunction is a common comorbidity in patients with CHF which entails a significant deleterious impact on patients' prognosis. 5 The clinical studies which have addressed the issue of renal effects of diuretics in CHF can be divided into observational cohort studies and prospective interventional studies. Regarding the former, their results are, in general, similar: use of loop diuretics is associated with an increased rate of renal dysfunction, 6 while accompanied by more pronounced renal function decline overtime. 7 Patients on high doses of loop diuretics (daily furosemide >80 mg) more often present with renal function deterioration (increase of serum creatinine >0.3 mg from baseline) and progression to end-stage renal disease (necessitating renal replacement therapy), irrespectively of the initial renal function. 8, 9 In a recent study, baseline dose of loop diuretics as well as maximal dose increase of diuretics were independent predictors of severe renal function worsening (> _0.5 mg/dL increase in serum creatinine compared to baseline). 10 Importantly, incidence of severe renal function deterioration was accompanied with a two-fold increased risk of death during the 18-month follow-up period compared to patients who presented with serum creatinine increases <0.5 mg/dL. In a sub-analysis of the same cohort, the relative effects of diuretics, beta-blockers and the renin-angiotensin-aldosterone system (RAS) inhibitors in patients presenting with and without severe renal function worsening were investigated. 11 The negative effects of high doses of loop diuretics on outcome were predominantly demonstrated in patients with severe renal function worsening; this could possibly indicate an underlying mechanism of diuretics' proposed, deleterious effects. Contrary, the beneficial effects of spironolactone were apparent in patients with severe renal function worsening, insinuating that creatinine increase should not be a reason for spironolactone decrease or withdrawal in patients with CHF; on the contrary, it should serve as red flag for careful monitoring of serum electrolytes. 12 This effect of spironolactone seems to be in line with findings of other studies that serum potassium levels below 3.9 mmol/L are associated with adverse outcome in patients receiving diuretics after a myocardial infarction. 13 Furthermore, beta-blockers were protective in all patients, but most in those with severe renal function worsening, while RAS-blockade was associated with improved outcome, irrespective of renal function deterioration. 12 As the authors insightfully discuss the often encountered clinical practice of reducing or even stopping these medication and up-titrating loop diuretics in an attempt to overcome resistance to diuretic therapy might not be appropriate.
In the second category, four prospective, interventional studies must be discussed; in the first, Galve et al.
14 discontinued the per os administered furosemide (mean 41 ± 9 mg/day) in 26 consecutive patients with stable systolic HF. At 3-month follow-up, 65% of the patients uneventfully tolerated furosemide discontinuation. The interruption of furosemide was accompanied by improvement in renal function, change which coincided with improved glucose metabolism, decreased plasma renin activity, but increased atrial natriuretic peptide levels. In another study per os diuretic therapy (furosemide dose 40-80 mg/day) was discontinued in thirty consecutive, euvolaemic patients with HF with reduced ejection fraction (HFrEF); 15 the diuretic treatment was reinstated per protocol after 3 days and indices of congestion and renal function were studied. Diuretic withdrawal led to significant increases in levels of atrial (ANP) and B-type natriuretic peptides (BNP), urinary kidney injury molecule (KIM)-1 and urinary N-acetyl-beta-D-glucosaminidase (NAG), which subsided after furosemide was reintroduced. The authors concluded that diuretic therapy may favourably affect renal and tubular function by decreasing congestion. Although the increases in serum level of ANP and BNP after diuretic withdrawal might suggest worsening of HF, the short-term discontinuation strategy hinders the deduction of relevant conclusions. Additionally, as BNP-guided tailoring of HF treatment has failed to convincingly show superiority compared to standard of care, 16 a clinically insignificant increase in natriuretic peptide levels might be the cost needed to be paid in order to reap the benefits of diuretics decrease described elsewhere. Finally, the disparity of the inclusion of some severely symptomatic (New York Heart Association class III) patients in this study needs to be highlighted. In another study, 17 ) and from 102 ± 13 mg to 57 ± 8 mg in the preserved GFR group. The authors reported that dose reduction was safe and was accompanied by a 19% increase in GFR in the low GFR group. Finally, in a study from our group, 18 forty stable patients with HFrEF on a high per os furosemide dose (> _120 mg daily) were randomly assigned in a 1:1 ratio to receive either their initial dose or one-third of it. Maintenance of decreased dose was feasible in 95% of the participants at 1 year. Renal function worsened in a significantly higher proportion of patients in the preserved compared to the decreased furosemide dose group (67% vs. 11%, P < 0.001).
Effects of loop diuretics on mortality and hospitalizations
The first studies that investigated the effect of diuretics withdrawal on patients' survival were performed decades ago. 3 However, as discussed elsewhere, 4 these studies are considered out of date and present several pitfalls, impeding the extrapolation of their results to current clinical practice. Nonetheless, they outline the long standing perception that diuretics are an indispensable weapon not only for the management of HF emergencies but also for the everyday treatment of CHF. Since then several studies have investigated the effect of diuretics use and dose on mortality and hospitalizations ( Tables 1 and  2 ). Cooper et al. 19 demonstrated in a large, cohort of HFrEF patients that receipt of a non-potassium-sparing diuretic (NPSD) at baseline was independently associated with increased incidence of arrhythmic death. Contrary, the receipt of a potassium-sparing diuretic did not effectuate such a risk. The same group demonstrated that patients on a NPSD were at a significantly higher risk of hospitalization or death due to worsening HF compared with patients not taking any diuretic. 20 These results were reinforced by another study, which associated NPSD use with increased risk of death, cardiovascular death, progressive HF death, sudden cardiac death, and HF hospitalization. 21 The potential harmful effects of diuretics in the setting of CHF have been supported by multiple other studies; in a study by Neuberg et al. 26 patients on high loop diuretics dose (175 ± 3.3 mg for furosemide and 4.7 ± 0.3 mg for bumetanide) demonstrated a higher risk for mortality, sudden death, and pump failure death when compared to patients on low diuretics dose (53 ± 0.9 mg for furosemide and 1.3 ± 0.1 mg for bumetanide), whereas in another cohort with advanced systolic HF the highest diuretic quartile (furosemide >160 mg/day) was designated as a significant predictor of increased mortality at 1-and at 2-year follow-up compared to the lowest diuretic quartile (furosemide <40 mg/day). 27 Others have also reported a significant association between diuretics dose (as a continuous variable) and risk for all-cause mortality, 32 and hospitalization for HF deterioration. 35 Furthermore, high doses of furosemide (>80 mg/day) have been highlighted as independent predictors of a composite endpoint of all-cause mortality, heart transplantation, and mechanical assist device implantation, 8 and death or hospital admission. 30 Furthermore, loop diuretic use at hospital discharge has been associated with risk for cardiac death and re-hospitalization during follow-up, 24 whereas exposure to medium (60-120 mg) and high daily furosemide doses(> _120 mg) within 1 year of hospital discharge among elderly patients with HF also had an independent predictive value for adverse clinical outcome during follow-up compared to exposure to low-furosemide doses (<60 mg). 29 Additionally, both lowdose (<40 mg/day) and high-dose (> _40 mg/day) loop diuretics were associated with a worse prognosis among 4134 consecutive patients with symptomatic stage C/D CHF. 25 Triple blockade with an angiotensin converting enzyme-i or an angiotensin receptor blocker, an mineralocorticoid receptor blocker and a b-blocker were associated with significantly better prognosis in patients receiving low, but not high dose loop diuretics in the same study. The adverse prognostic value of diuretics dose (as a continuous variable) has also been demonstrated in a cohort of patients treated with cardiac resynchronization therapy. 34 Patients on higher doses had a significantly higher risk for all-cause mortality during follow-up. Despite the accumulating data, some authors have challenged the proposed causal relationship between diuretics and adverse outcome; specifically, they have suggested that confounding by indication may account for this association, designating higher doses as a marker of disease severity, rather than a true risk factor. 28, 36 Nonetheless, several studies have aided weaken the basis of this argument. Testani et al. 31 insightfully investigated whether different levels of blood urea nitrogen (BUN), which is a marker of renal neurohormonal activation, could distinguish between patients who would demonstrate an adverse prognosis while treated with high doses of loop diuretics. Figure 1 Proposed algorithm for diuretics dose reduction in patients with chronic heart failure. *Last hospitalization and/or NYHA change and/ or diuretic dose change >3 months ago and no heart failure medication change for at least 1 month; **Recommended standard laboratory panel containing, but not limited to: haemoglobin, blood urea nitrogen, creatinine, potassium, sodium, magnesium, glucose, uric acid, NT-proBNP. ***Tx, treatment; BUN, blood urea nitrogen.
Diuretics for chronic heart failure The authors reported that high doses of loop diuretics (> _160 mg of furosemide or equivalents) were independently associated with a higher risk of death in subjects with BUN levels above the median (21 mg/dL), but not in those with BUN levels below the median. Conversely, in patients of the latter group, high doses of loop diuretics were associated with a lower risk of death after multivariate adjustment, denoting neurohormonal activation as a potential underlying mechanism by which the dismal effects of diuretics are mediated. Other studies have utilized an extensive propensity score matching method in order to adjust for the differences in the severity of HF between patients when investigating for the prognostic significance of diuretics. In analyses from two propensity matched populations derived from the DIG trial, diuretic use was independently associated with increased mortality and hospitalizations in patients with both HFrEF and HF with preserved ejection fraction, 22 as well as in a subgroup of patients > _65 years old. 23 The risk of death increased across quartiles of furosemide daily dose (no furosemide vs. <25 mg/ day vs. 26-50 mg/day vs. >50 mg/day), after stratification for the propensity score, in a study of 813 consecutive outpatients with HFrEF. 33 Additionally, loop diuretic use was associated with a higher risk of cardiovascular mortality and HF-related hospitalization 7 ; the risk increased for each 40 mg incremental increase of furosemide. Finally, in a small randomized study of stable HFrEF patients, 18 we demonstrated a significantly higher incidence of the composite of cardiac death or HF-related hospitalization in the preserved compared to the decreased furosemide dose group at 1 (25% vs. 0%) and 2 years of follow-up (55% vs. 25%). This unfavourable outcome was paralleled by deterioration of renal function and decrease of haemoglobin in the preserved furosemide dose group, possibly pinpointing some of the mechanisms by which diuretics exert their deleterious effects.
Although the results of the presented studies converge to the notion that diuretics use, especially in increased doses, might exert detrimental effects on the outcomes of patients with CHF, several pitfalls hindering definite conclusion formation must be stressed: first of all, the examined studies cover a 20-year time span, during which many aspects of HF-related treatment have changed. Furthermore, patient populations differed significantly among the aforementioned studies. Additionally, 'high' diuretics dose was arbitrarily and not universally defined among the same studies. Moreover, most of the analysed studies were observational and adjustment for all confounding factors and especially diuretics indication use is not possible. For these reasons, generalization and extrapolation of results must be performed with extreme caution.
Conclusion
Although loop diuretics represent the mainstay of treating congestion in patients with CHF, their effects remain largely understudied. Despite the older perception that their use may provide a survival benefit in CHF, a large body of evidence has put this notion in dispute; loop diuretics use, especially in high doses, may adversely affect prognosis in CHF patients, potentially by instigating neurohormonal activation and renal dysfunction. In any case, many important issues regarding the use of diuretics remain unsettled: what is the optimal dosing up-and down-titration algorithm? When can a patient be considered clinically stable and euvolaemic? Which are the clinical and paraclinical signs or biomarkers which can indicate that diuretics are prescribed in excess of clinical needs, as frequently observed? 37 Which markers can aid dose adjustment tailoring? Only future, large studies will answer these pending issues and enable evidence-based use of diuretics in CHF. Until then, and based on the few existing data, the dose of loop diuretics in patients with CHF and no symptoms and sign of congestion should be cautiously reduced to the minimum levels required to maintain euvolaemia, according to the algorithm proposed (Figure 1) .
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